Curto Sánchez E., Ojanguren Arranz Í., Blanco-Aparicio M., Crespo-Lessmann A., Plaza Moral V., Cisneros Serrano C., Serrano Pariente J.. How to Approach Non Eosinophilic Asthma? Results of a Survey Conducted by the SEPAR Emerging Asthma Group. Open Respiratory Archives. 2022; 4(1)DOI:10.1016/j.opresp.2021.100149. PMID:. IF:(Q/D).

Martinez-Garcia M.A., Oscullo G., Ponce S., Pastor E., Orosa B., Catalán P., Martinez A., Hernandez L., Muriel A., Chiner E., Vigil L., Carmona C., Mayos M., Garcia-Ortega A., Gomez-Olivas J.D., Beauperthuy T., Bekki A., Gozal D.. Effect of continuous positive airway pressure in very elderly with moderate-to-severe obstructive sleep apnea pooled results from two multicenter randomized controlled trials. SLEEP MEDICINE. 2022; 89DOI:10.1016/j.sleep.2021.11.009. PMID:34915264. IF:4.800(Q1/3D).

Cozzi-Lepri A., Peters L., Pelchen-Matthews A., Neesgaard B., Stephan C., Elbirt D., Brännström J., Paduta D., Trofimova T., Szlavik J., Van Eygen V., Pai H., Lundgren J., Harxhi A., Losso M., Kundro M., Schmied B., Karpov I., Vassilenko A., Paduto D., Mitsura V.M., Clumeck N., De Wit S., Delforge M., Hadziosmanovic V., Begovac J., Machala L., Jilich D., Gerstoft J., Pedersen C., Sedlacek D., Kronborg G., Benfield T., Johansen I.S., Ostergaard L., Wiese L., Moller N.F., Nielsen L.N., Zilmer K., Smidt J., Aho I., Viard J.P., Girard P.M., Pradier C., Fontas E., Duvivier C., Rockstroh J., Degen O., Hoffmann C., Stellbrink H.J., Stefan C., Bogner J., Fätkenheuer G., Chkhartishvili N., Sambatakou H., Adamis G., Paissios N., Uzdaviniene V., Staub T., Dragas S., Reiss P., Trajanovska J., Reikvam D.H., Maeland A., Bruun J., Knysz B., Szetela B., Inglot M., Bakowska E., Flisiak R., Grzeszczuk A., Parczewski M., Maciejewska K., Aksak-Was B., Beniowski M., Mularska E., Jablonowska E., Kamerys J., Wojcik K., Mozer-Lisewska I., Rozplochowski B., Zagalo A., Radoi R., Oprea C., Yakovlev A., Trofimora T., Khromova I., Kuzovatova E., Borodulina E., Vdoushkina E., Ranin J., Tomazic J., Miro J.M., Laguno M., Martinez E., Garcia F., Blanco J.L., Martinez-Rebollar M., Mallolas J., Callau P., Rojas J., Moreno S., del Campo S., Jou A., Paredes R., Puig J., Llibre J.M., Santos J.R., Domingo P., Gutierrez M., Mateo G.M., Sambeat A., Laporte J.M., Svedhem V., Thalme A., Sonnerborg A., Flamholc L., Kusejko K., Weber R., Calmy A., Furrer H., Battegay M., Schmid P., Kuznetsova A., Mikhalik J., Sluzhynska M., Milinkovic A., Johnson A.M., Simons E., Edwards S., Phillips A.M., Johnson A., Mocroft A., Orkin C., Winston A., Clarke A., Leen C.. Observational cohort study of rilpivirine (RPV) utilization in Europe. AIDS Research and Therapy. 2022; 19(1)DOI:10.1186/s12981-022-00457-0. PMID:35933352. IF:2.200(Q4/8D).

Martin-Iguacel R., Reyes-Urueña J., Bruguera A., Aceitón J., Díaz Y., Moreno-Fornés S., Domingo P., Burgos-Cibrian J., Tiraboschi J.M., Johansen I.S., Álvarez H., Miró J.M., Casabona J., Llibre J.M.. Determinants of long-term survival in late HIV presenters: The prospective PISCIS cohort study. Eclinicalmedicine. 2022; 52DOI:10.1016/j.eclinm.2022.101600. PMID:35958520. IF:15.100(Q1/1D).

Garreta E., Prado P., Stanifer M.L., Monteil V., Marco A., Ullate-Agote A., Moya-Rull D., Vilas-Zornoza A., Tarantino C., Romero J.P., Jonsson G., Oria R., Leopoldi A., Hagelkruys A., Gallo M., González F., Domingo-Pedrol P., Gavaldà A., del Pozo C.H., Hasan Ali O., Ventura-Aguiar P., Campistol J.M., Prosper F., Mirazimi A., Boulant S., Penninger J.M., Montserrat N.. A diabetic milieu increases ACE2 expression and cellular susceptibility to SARS-CoV-2 infections in human kidney organoids and patient cells. Cell Metabolism. 2022; 34(6)DOI:10.1016/j.cmet.2022.04.009. PMID:35561674. IF:29.000(Q1/1D).

Trickey A., Zhang L., Gill M.J., Bonnet F., Burkholder G., Castagna A., Cavassini M., Cichon P., Crane H., Domingo P., Grabar S., Guest J., Obel N., Psichogiou M., Rava M., Reiss P., Rentsch C.T., Riera M., Schuettfort G., Silverberg M.J., Smith C., Stecher M., Sterling T.R., Ingle S.M., Sabin C.A., Sterne J.A.C.. Associations of modern initial antiretroviral drug regimens with all-cause mortality in adults with HIV in Europe and North America: a cohort study. Lancet HIV. 2022; 9(6)DOI:10.1016/S2352-3018(22)00046-7. PMID:35659335. IF:(Q/D).

Riancho J.A., Peris P., González-Macías J., Pérez-Castrillón J.L., Cannata Andía J., Cano A., Carbonell Abella C., Casado Burgos E., Ciria Recasens M., Corral-Gudino L., del Pino Montes J., Del Río Barquero L.M., Díaz Curiel M., Díez Pérez A., García Vadillo A., Gómez Alonso C., Gómez de Tejada Romero M.J., Guañabens N., Hawkins Carranza F., Jódar Gimeno E., Malouf Sierra J., Martínez Díaz-Guerra G., Monegal Brancos A., Muñoz Torres M., Naves Díaz M., Nogues X., Nolla J.M., Olmos Martínez J.M., Peris Bernal P., Quesada Gómez J.M., Rodríguez García M., Sosa Henríquez M., Torrijos Eslava A., Valero Díaz de Lamadrid C.. Executive summary clinical practice guideline of postmenopausal, glucocorticoid-induced, and male osteoporosis (2022 update). Revista De Osteoporosis Y Metabolismo Mineral. 2022; 14(1)DOI:10.4321/S1889-836X2022000100002. PMID:. IF:(Q/D).

Encarnacion, JA, Cerezuela, P, Espanol, I, Garcia, MR, Manso, C, De la Fuente, I, Garrigos, N, Viney, A, Minguillon, J, Surralles, J. Fanconi-like anemia related to a FANCM mutation. European Journal of Medical Genetics. 2022; 65(1)DOI:10.1016/j.ejmg.2021.104399. PMID:34793962. IF:1.900(Q4/8D).

Minguillon, J, Ramirez, MJ, Rovirosa, L, Bustamante-Madrid, P, Camps-Fajol, C, de Garibay, GR, Shimelis, H, Montanuy, H, Pujol, R, Hernandez, G, Bogliolo, M, Castillo, P, Soucy, P, Martrat, G, Gomez, A, Cuadras, D, Garcia, MJ, Gayarre, J, Lazaro, C, Benitez, J, Couch, FJ, Pujana, MA, Surralles, J. CDK5RAP3, a New BRCA2 Partner That Regulates DNA Repair, Is Associated with Breast Cancer Survival. Cancers. 2022; 14(2)DOI:10.3390/cancers14020353. PMID:35053516. IF:5.200(Q2/3D).

Webster A.L.H., Sanders M.A., Patel K., Dietrich R., Noonan R.J., Lach F.P., White R.R., Goldfarb A., Hadi K., Edwards M.M., Donovan F.X., Hoogenboezem R.M., Jung M., Sridhar S., Wiley T.F., Fedrigo O., Tian H., Rosiene J., Heineman T., Kennedy J.A., Bean L., Rosti R.O., Tryon R., Gonzalez A.-M., Rosenberg A., Luo J.-D., Carroll T.S., Shroff S., Beaumont M., Velleuer E., Rastatter J.C., Wells S.I., Surrallés J., Bagby G., MacMillan M.L., Wagner J.E., Cancio M., Boulad F., Scognamiglio T., Vaughan R., Beaumont K.G., Koren A., Imielinski M., Chandrasekharappa S.C., Auerbach A.D., Singh B., Kutler D.I., Campbell P.J., Smogorzewska A.. Genomic signature of Fanconi anaemia DNA repair pathway deficiency in cancer. NATURE. 2022; 612(7940)DOI:10.1038/s41586-022-05253-4. PMID:36450981. IF:64.800(Q1/1D).

Errazquin R., Page A., Suñol A., Segrelles C., Carrasco E., Peral J., Garrido-Aranda A., Del Marro S., Ortiz J., Lorz C., Minguillon J., Surralles J., Belendez C., Alvarez M., Balmaña J., Bravo A., Ramirez A., Garcia-Escudero R.. Development of a mouse model for spontaneous oral squamous cell carcinoma in Fanconi anemia. ORAL ONCOLOGY. 2022; 134DOI:10.1016/j.oraloncology.2022.106184. PMID:36191479. IF:4.800(Q1/1D).

Blay, JY, Hindi, N, Bollard, J, Aguiar, S, Angel, M, Araya, B, Badilla, R, Bernabeu, D, Campos, F, Caro-Sanchez, CHS, Carvajal, B, Montoya, AC, Casavilca-Zambrano, S, Castro-Oliden, V, Chacon, M, Clara, M, Collini, P, Genoroso, RC, Costa, FD, Cuellar, M, dei Tos, AP, Malagon, HRD, Donati, D, Dufresne, A, Eriksson, M, Farias-Loza, M, Fernandez, P, Frezza, AM, Frisoni, T, Garcia-Ortega, DY, Gelderblom, H, Gouin, F, Gomez-Mateo, MC, Gronchi, A, Haro, J, Huanca, L, Jimenez, N, Karanian, M, Kasper, B, David, BBL, Lopez-Pousa, A, Lutter, G, Martinez-Said, H, Martinez-Tlahuel, J, Mello, CA, Perez, JMM, David, SM, Nascimento, AG, Ortiz-Cruz, EJ, Palmerini, E, Patel, S, Pfluger, Y, Provenzano, S, Righi, A, Rodriguez, A, Salas, R, Santos, TTG, Scotlandi, K, Soule, T, Stacchiotti, S, Valverde, C, Waisberg, F, Estrada, EZ, Martin-Broto, J. SELNET clinical practice guidelines for soft tissue sarcoma and GIST. CANCER TREATMENT REVIEWS. 2022; 102DOI:10.1016/j.ctrv.2021.102312. PMID:34798363. IF:11.800(Q1/1D).

Provencio, M, Rodriguez-Abreu, D, Ortega, AL, Serrano, G, Aguado, C, Franco, F, Gutierrez, V, Vivanco, GL, Guirado, M, Benitez, G, Estival, A, Calvo, V, Jimenez, B, Arasanz, H, Coves, J, Majem, M, Massuti, B, Vazquez, S, Juan-Vidal, O, Collazo-Lorduy, A, Gozalvez, CL, Del Barco, E, Rosero, A, Bosch-Barrerra, J, Moreno, MA, Mielgo-Rubio, X, Villa, JC, Lopez-Martin, A, Cordoba, JF, Aparisi, FD, Zafra, M, Mosquera, J, Altozano, JP, Nadal, E, Catot, S, Balsalobre, J, De Portugal, T, Martin, P, De Juan, SC, Cobo, M. Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study. Translational Lung Cancer Research. 2022; 11(1)DOI:10.21037/tlcr-21-504. PMID:35242627. IF:4.000(Q2/4D).

Kuemmel, S, Campone, M, Loirat, D, Lopez, RL, Beck, JT, De Laurentiis, M, Im, SA, Kim, SB, Kwong, A, Steger, GG, Adelantado, EZ, Duhoux, FP, Greil, R, Kuter, I, Lu, YS, Tibau, A, Ozguroglu, M, Scholz, CW, Singer, CF, Vega, E, Wimberger, P, Zamagni, C, Couillebault, XM, Fan, LQ, Guerreiro, N, Mataraza, J, Sand-Dejmek, J, Chan, A. A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer. CLINICAL CANCER RESEARCH. 2022; 28(1)DOI:10.1158/1078-0432.CCR-20-3955. PMID:34615719. IF:11.500(Q1/1D).

Adam, R, Tibau, A, Valiente, CM, Seruga, B, Ocana, A, Amir, E, Templeton, AJ. Clinical benefit of cancer drugs approved in Switzerland 2010-2019. PLoS One. 2022; 17(6)DOI:10.1371/journal.pone.0268545. PMID:35687539. IF:3.700(Q2/4D).

Hernandez, MH, Bote, V, Serra-LLovich, A, Cendros, M, Salazar, J, Mestres, C, Guijarro, S, Alvarez, A, Lamborena, C, Mendez, I, Sanchez, B, Hervas, A, Arranz, MJ. CES1 and SLC6A2 Genetic Variants As Predictors of Response To Methylphenidate in Autism Spectrum Disorders. Pharmacogenomics & Personalized Medicine. 2022; 15DOI:10.2147/PGPM.S377210. PMID:36393977. IF:1.900(Q4/9D).

Molto C., Tibau A., Bujosa A., Tapia J.C., Mittal A., Tamimi F., Amir E.. Association between control group therapy and magnitude of clinical benefit of cancer drugs. Scientific Reports. 2022; 12(1)DOI:10.1038/s41598-022-25983-9. PMID:36494465. IF:(Q/D).

Isla D., Majem M.. A Paradigm Shift for Resectable Non-Small Cell Lung Cancer. ARCHIVOS DE BRONCONEUMOLOGIA. 2022; 58(12)DOI:10.1016/j.arbres.2022.04.004. PMID:35595655. IF:8.000(Q1/2D).

Argilés G., Valladares-Ayerbes M., Viéitez J.M., García-Paredes B., Rodríguez-Garrote M., Rivera F., Goldberg R.M., Ciardiello F., Tabernero J.M., Goldberg R., Argilés, Tabernero J., Mulet N., Limón M.L., Valladares M., Jiménez P., Vieitez J.M., Grávalos C., García-Alfonso P., Santos C., Páez D., Tobeña M., Sastre J., García Paredes B., Benavides M., Aranda E., Cano M.T., Loupakis F., Rguez Garrote M., Guillén C., Rivera M.F., Safont J., Hiret S., Bennouna J., Pannier D., Malka D., Falcone A., Cremolini C., The. A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial). EUROPEAN JOURNAL OF CANCER. 2022; 177DOI:10.1016/j.ejca.2022.09.037. PMID:36335783. IF:8.400(Q1/2D).

Martin-Broto J., Redondo A., Moura D.S., Valverde C., Morales J.M., Lopez-Pousa A., Martinez-Trufero J., Gutierrez A., Díaz-Beveridge R., Luna P., Martinez-Marin V., Marcilla D., Arribas I., Ledesma P., Lopez-Martin J.A., Di Lernia D., Zamora J., Hindi N.. A phase II trial of weekly nab-paclitaxel for progressive and symptomatic desmoid tumors. Nature Communications. 2022; 13(1)DOI:10.1038/s41467-022-33975-6. PMID:36271011. IF:16.600(Q1/1D).

Blay J.Y., Palmerini E., Bollard J., Aguiar S., Angel M., Araya B., Badilla R., Bernabeu D., Campos F., Chs C.-S., Carvajal Montoya A., Casavilca-Zambrano S., Castro-Oliden, 5th, Chacón M., Clara-Altamirano M.A., Collini P., Correa Genoroso R., Costa F.D., Cuellar M., Dei Tos A.P., Dominguez Malagon H.R., Donati D.M., Dufresne A., Eriksson M., Farias-Loza M., Frezza A.M., Frisoni T., Garcia-Ortega D.Y., Gerderblom H., Gouin F., Gómez-Mateo M.C., Gronchi A., Haro J., Hindi N., Huanca L., Jimenez N., Karanian M., Kasper B., Lopes A., Lopes David B.B., Lopez-Pousa A., Lutter G., Maki R.G., Martinez-Said H., Martinez-Tlahuel J.L., Mello C.A., Morales Pérez J.M., Moura D.S., Nakagawa S.A., Nascimento A.G., Ortiz-Cruz E.J., Patel S., Pfluger Y., Provenzano S., Righi A., Rodriguez A., Santos T.G., Scotlandi K., Mlg S., Soulé T., Stacchiotti S., Valverde C.M., Waisberg F., Zamora Estrada E., Martin-Broto J.. Corrigendum to “SELNET clinical practice guidelines for bone sarcoma” Critical reviews in oncology/hematology, vol. 174 (2022), 1–10 (Critical Reviews in Oncology / Hematology (2022) 174, (S1040842822001093), (10.1016/j.critrevonc.2022.103685)). CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2022; 180DOI:10.1016/j.critrevonc.2022.103827. PMID:36220678. IF:6.200(Q1/3D).

Salvador Bofill J., Moreno Anton F., Rodriguez Sanchez C.A., Galve Calvo E., Hernando Melia C., Ciruelos Gil E.M., Vidal M., Jiménez-Rodriguez B., De la Cruz Merino L., Martínez Jañez N., Villanueva Vazquez R., de Toro Salas R., Anton Torres A., Alvarez Lopez I.M., Gavila Gregori J., Quiroga Garcia V., Vicente Rubio E., De la Haba-Rodriguez J., Gonzalez-Santiago S., Diaz Fernandez N., Barnadas Molins A., Cantos Sanchez de Ibargüen B., Delgado Mingorance J.I., Bellet Ezquerra M., de Casa S., Gimeno A., Martin M.. Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial. BREAST. 2022; 66DOI:10.1016/j.breast.2022.09.006. PMID:36206609. IF:3.900(Q1/3D).

Pena-Couso L., Ercibengoa M., Mercadillo F., Gómez-Sánchez D., Inglada-Pérez L., Santos M., Lanillos J., Gutiérrez-Abad D., Hernández A., Carbonell P., Letón R., Robledo M., Rodríguez-Antona C., Perea J., Urioste M., Alonso M.Á., Andrés R., Arévalo S., del Mar Arias M., Balmaña J., Beristain E., Blanco I., Boronat M., Brunet J., Cózar M.V., del Campo M., Díaz A., Gabau E., Barcina M.J., González M., Guitart M., Hernán I., Hernández H.S., Hernando S., Lacambra C., Lasa A., Lastra E., Llort G., del Rosario Marín M., Marrupe D., Martínez F., Martínez V., Martorell L., Orera M., Pedrinaci S., Pérez P., Pineda M., Plasencia A.M., Cajal T.R., Robles L., Rodà D., Rodríguez N., Rosell J., Sáez R., Salvat M., Sánchez A., Santana A., Soto J.L., Toll A., Tuneu A., Vázquez C.. Considerations on diagnosis and surveillance measures of PTEN hamartoma tumor syndrome: clinical and genetic study in a series of Spanish patients. Orphanet Journal of Rare Diseases. 2022; 17(1)DOI:10.1186/s13023-021-02079-7. PMID:35227301. IF:3.700(Q2/4D).

Hidalgo-Ríos S., Carrillo-García J., Moura D.S., Stacchiotti S., López-Pousa A., Redondo A., Italiano A., Gutiérrez A., Grignani G., Hindi N., López-Guerrero J.-A., Muro X.G.D., Trufero J.M., Palmerini E., García A.S., Bernabeu D., Le Cesne A., Casali P.G., Blay J.-Y., Cruz Jurado J., Martin-Broto J.. Peripheral Inflammatory Indexes Neutrophil/Lymphocyte Ratio (NLR) and Red Cell Distribution Width (RDW) as Prognostic Biomarkers in Advanced Solitary Fibrous Tumour (SFT) Treated with Pazopanib. Cancers. 2022; 14(17)DOI:10.3390/cancers14174186. PMID:36077723. IF:5.200(Q2/3D).

Bellmunt J., Valderrama B.P., Puente J., Grande E., Bolós M.V., Lainez N., Vázquez S., Maroto P., Climent M.Á., Garcia del Muro X., Arranz J.Á., Durán I.. Recent therapeutic advances in urothelial carcinoma: A paradigm shift in disease management. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2022; 174DOI:10.1016/j.critrevonc.2022.103683. PMID:35439541. IF:6.200(Q1/3D).

Aguado-Flor E., Fuentes-Raspall M.J., Gonzalo R., Alonso C., Ramón y Cajal T., Fisas D., Seoane A., Sánchez-Pla Á., Giralt J., Díez O., Gutiérrez-Enríquez S.. Cell Senescence-Related Pathways Are Enriched in Breast Cancer Patients With Late Toxicity After Radiotherapy and Low Radiation-Induced Lymphocyte Apoptosis. Frontiers in Oncology. 2022; 12DOI:10.3389/fonc.2022.825703. PMID:35686103. IF:4.700(Q2/4D).

Provencio M., Serna-Blasco R., Nadal E., Insa A., García-Campelo M.R., Casal Rubio J., Dómine M., Majem M., Rodríguez-Abreu D., Martínez-Martí A., De Castro Carpeño J., Cobo M., López Vivanco G., Del Barco E., Bernabé Caro R., Viñolas N., Barneto Aranda I., Viteri S., Pereira E., Royuela A., Calvo V., Martín-López J., García-García F., Casarrubios M., Franco F., Sánchez-Herrero E., Massuti B., Cruz-Bermúdez A., Romero A.. Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial). JOURNAL OF CLINICAL ONCOLOGY. 2022; 71DOI:10.1200/JCO.21.02660. PMID:35576508. IF:45.300(Q1/1D).

Riudavets M., Auclin E., Mosteiro M., Dempsey N., Majem M., Lobefaro R., López-Castro R., Bosch-Barrera J., Pilotto S., Escalera E., Tagliamento M., Mosquera J., Zalcman G., Aboubakar-Nana F., Ponce S., Dal Maso A., Spotti M., Mielgo-Rubio X., Mussat E., Reyes R., Benítez J.-C., Lupinacci L., Duchemann B., De Giglio A., Blaquier J., Audigier-Valette C., Scheffler M., Nadal E., Lopes G., Signorelli D., Garcia-Campelo R., Menis J., Bluthgen V., Campayo M., Recondo G., Besse B., Planchard D., Mezquita L.. Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations. EUROPEAN JOURNAL OF CANCER. 2022; 167DOI:10.1016/j.ejca.2022.02.014. PMID:35307254. IF:8.400(Q1/2D).

Bernabé-Caro R., Garrido P., García-Campelo R., Palmero R., Artal Á., Bayona C., Rodríguez-Abreu D., López-Brea M., Paredes A., Vicente D., Torres J.M.S., Majem M., Diz P., Gordo R., Coca M., de Castro J.. Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program. Oncotarget. 2022; 13(1)DOI:10.18632/oncotarget.28244. PMID:. IF:(Q/D).

Peters S., Pujol J.-L., Dafni U., Dómine M., Popat S., Reck M., Andrade J., Becker A., Moro-Sibilot D., Curioni-Fontecedro A., Molinier O., Nackaerts K., Insa Mollá A., Gervais R., López Vivanco G., Madelaine J., Mazieres J., Faehling M., Griesinger F., Majem M., González Larriba J.L., Provencio Pulla M., Vervita K., Roschitzki-Voser H., Ruepp B., Mitchell P., Stahel R.A., Le Pechoux C., De Ruysscher D., Stahel R., Hiltbrunner A., Pardo-Contreras M., Gasca-Ruchti A., Giacomelli N., Kammler R., Marti N., Pfister R., Piguet A.C., Roux S., Troesch S., Schneider M., Schweri R., Zigomo I., Tsourti Z., Zygoura P., Tsouprou S., Kassapian M., Dimopoulou G., Andriakopoulou C., Morin F., Amour E., Mariaule G., Archirel N., Fernandez M., Pereira E., Benito L., Lopez K., Hernández A., Chinchen S., Jurkovic H., Livingstone A., Mitchell J., Walker M., Ng S., Steer C., Briscoe K., Saqib A., Abdi E., Houghton B., O'Byrne K., Chittajallu B.R., Hughes B.G., Black A., Werner H., Zalcman G., Vaylet F., Merle P., Monnet I., Girard N., Souquet P.-J., Barlesi F., Debieuvre D., Senellart H., Poudenx M., Dixmier A., Pouessel D., Cadranel J., Lena H., Quoix E., Friard S., Audigier-Valette C., Pichon E., Kokowski K., Kirchen H., Tufman A., De-Colle C., de Langen J., Insa A., Massutí B., Pulla M.P., Aix S.P., Villanueva N., Vivanco G.L., Franks K., Califano R.. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial. ANNALS OF ONCOLOGY. 2022; 33(1)DOI:10.1016/j.annonc.2021.09.011. PMID:34562610. IF:50.500(Q1/1D).

López-Laguna H, Voltà-Durán E, Parladé E, Villaverde A, Vázquez E, Unzueta U. Insights on the emerging biotechnology of histidine-rich peptides. BIOTECHNOLOGY ADVANCES. 2022; 54DOI:10.1016/j.biotechadv.2021.107817. PMID:34418503. IF:16.000(Q1/1D).

Pasquali, S, Palmerini, E, Quagliuolo, V, Martin-Broto, J, Lopez-Pousa, A, Grignani, G, Brunello, A, Blay, JY, Tendero, O, Diaz-Beveridge, R, Ferraresi, V, Lugowska, I, Infante, G, Braglia, L, Merlo, DF, Fontana, V, Marchesi, E, Donati, DM, Palassini, E, Bianchi, G, Marrari, A, Morosi, C, Stacchiotti, S, Bague, S, Coindre, JM, Dei Tos, AP, Picci, P, Bruzzi, P, Miceli, R, Casali, PG, Gronchi, A. Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial. CANCER. 2022; 128(1)DOI:10.1002/cncr.33895. PMID:34643947. IF:6.200(Q1/3D).

Serra C., Torrego A., Pajares V., Millan-Billi P., Barril S., Alonso A., Navarro M., Lopez L., Franquet T., Castillo D.. Bronchoalveolar lavage complements transbronchial cryobiopsy diagnosis in diffuse interstitial lung diseases. JOURNAL OF BRONCHOLOGY & INTERVENTIONAL PULMONOLOGY. 2022; 29(1)DOI:10.1097/LBR.0000000000000770. PMID:33828048. IF:(Q/D).

Rojas-Lechuga, MJ, Gras-Cabrerizo, JR, Aviles-Jurado, FX, Malvehy, J, Arance, AM, Castillo, P, Barreiro, A, Podlipnik, S, Lopez-Chacon, M, Alobid, I, Sprekelsen, MB, Puig, S, Langdon, C. Sinonasal mucosal melanomas: defining profiles for better survival outcomes. RHINOLOGY. 2022; 60(5)DOI:10.4193/Rhin21.251. PMID:36184882. IF:7.200(Q1/1D).

Pinana, JL, Lopez-Corral, L, Martino, R, Montoro, J, Vazquez, L, Perez, A, Martin-Martin, G, Facal-Malvar, A, Ferrer, E, Pascual, MJ, Sanz-Linares, G, Gago, B, Sanchez-Salinas, A, Villalon, L, Conesa-Garcia, V, Olave, MT, Lopez-Jimenez, J, Marcos-Corrales, S, Garcia-Blazquez, M, Garcia-Gutierrez, V, Hernandez-Rivas, JA, Saus, A, Espigado, I, Alonso, C, Hernani, R, Solano, C, Ferrer-Lores, B, Guerreiro, M, Ruiz-Garcia, M, Munoz-Bellido, JL, Navarro, D, Cedillo, A, Sureda, A. SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group. AMERICAN JOURNAL OF HEMATOLOGY. 2022; 97(1)DOI:10.1002/ajh.26385. PMID:34695229. IF:12.800(Q1/1D).

Kanda, J, Hayashi, H, Ruggeri, A, Kimura, F, Volt, F, Takahashi, S, Kako, S, Tozatto-Maio, K, Yanada, M, Sanz, G, Uchida, N, Angelucci, E, Kato, S, Mohty, M, Forcade, E, Tanaka, M, Sierra, J, Ohta, T, Saccardi, R, Fukuda, T, Ichinohe, T, Kimura, T, Rocha, V, Okamoto, S, Nagler, A, Atsuta, Y, Gluckman, E. The impact of GVHD on outcomes after adult single cord blood transplantation in European and Japanese populations. BONE MARROW TRANSPLANTATION. 2022; 57(1)DOI:10.1038/s41409-021-01479-4. PMID:34635798. IF:4.800(Q1/2D).

Rucker, FG, Du, L, Luck, TJ, Benner, A, Krzykalla, J, Gathmann, I, Voso, MT, Amadori, S, Prior, TW, Brandwein, JM, Appelbaum, FR, Medeiros, BC, Tallman, MS, Savoie, L, Sierra, J, Pallaud, C, Sanz, MA, Jansen, JH, Niederwieser, D, Fischer, T, Ehninger, G, Heuser, M, Ganser, A, Bullinger, L, Larson, RA, Bloomfield, CD, Stone, RM, Dohner, H, Thiede, C, Dohner, K. Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. LEUKEMIA. 2022; 36(1)DOI:10.1038/s41375-021-01323-0. PMID:34316017. IF:11.400(Q1/1D).

Pallares, V, Unzueta, U, Falgas, A, Avino, A, Nunez, Y, Garcia-Leon, A, Sanchez-Garcia, L, Serna, N, Gallardo, A, Alba-Castellon, L, Alamo, P, Sierra, J, Cedo, L, Eritja, R, Villaverde, A, Vazquez, E, Casanova, I, Mangues, R. A multivalent Ara-C-prodrug nanoconjugate achieves selective ablation of leukemic cells in an acute myeloid leukemia mouse model. BIOMATERIALS. 2022; 280DOI:10.1016/j.biomaterials.2021.121258. PMID:34847435. IF:14.000(Q1/1D).

Mikulska, M, Knelange, N, Nicolini, LA, Tridello, G, Santarone, S, Di Bartolomeo, P, de la Camara, R, Cuellar, C, Velardi, A, Perruccio, K, Ljungman, P, Zaucha, J, Piekarska, A, Basak, G, Karakulska-Prystupiuk, E, Angelucci, E, Ciceri, F, Lupo-Stanghellini, MT, Fouillard, L, Garcia-Cadenas, I, Menconi, M, Blau, IW, Nassi, L, Cesaro, S, Styczynski, J. Efficacy, safety and feasibility of treatment of chronic HCV infection with directly acting agents in hematopoietic stem cell transplant recipients - Study of infectious diseases working party of EBMT. JOURNAL OF INFECTION. 2022; 84(1)DOI:10.1016/j.jinf.2021.10.024. PMID:34757138. IF:28.200(Q1/1D).

Serna, N, Falgas, A, Garcia-Leon, A, Unzueta, U, Nunez, Y, Sanchez-Chardi, A, Martinez-Torro, C, Mangues, R, Vazquez, E, Casanova, I, Villaverde, A. Time-Prolonged Release of Tumor-Targeted Protein-MMAE Nanoconjugates from Implantable Hybrid Materials. Pharmaceutics. 2022; 14(1)DOI:10.3390/pharmaceutics14010192. PMID:35057088. IF:5.400(Q1/2D).